Predictors of relapse and prophylactic management of immune thrombotic thrombocytopenic purpura.

Authors :: Oliver M
Patriquin CJ
Pavenski K
Source :: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2023 Aug; Vol. 62 (4), pp. 103749. Date of Electronic Publication: 2023 Jun 10.
Publication Year :: 2023
Abstract: Competing Interests: Declaration of Competing Interest MO has participated in industry trials for Alexion and consulted for Alexion, Roche, Sobi and Takeda. CJP has participated in industry trials (Alexion, Apellis, Regeneron, Sanofi) and has consulted for Alexion, Apellis, BioCryst, Regeneron, Roche, Sanofi, Sobi, and Takeda. KP has participated in industry trials (Ablynx/Sanofi, Shire/Takeda) and has consulted for Sanofi and Takeda.

Subjects :: Humans
Plasma Exchange
Recurrence
ADAMTS13 Protein
Purpura, Thrombotic Thrombocytopenic therapy
Purpura, Thrombocytopenic, Idiopathic

Language :: English
ISSN :: 1473-0502
Volume :: 62
Issue :: 4
Database :: MEDLINE
Journal :: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Publication Type :: Academic Journal
Accession number :: 37344323
Full Text :: https://doi.org/10.1016/j.transci.2023.103749

Full Text Access

Tools